Caris Life Sciences, Inc. key statistics and ratios

In fiscal 2025, Caris Life Sciences, Inc. had an operating margin of 5.6%, debt equal to 65.6% of equity and a current ratio of 7.85. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Caris Life Sciences, Inc.: financial ratios, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Operating margin	−104.4%	−62.4%	5.6%	15.5%
Net margin	−111.5%	−68.4%	−8.4%	10.6%
Free-cash-flow margin	−97.5%	−61.5%	8.2%	12.5%
Return on equity	—	—	—	18.0%
Return on assets	—	−82.0%	−9.3%	8.9%
Asset turnover	—	1.20	1.11	0.84
Current ratio	—	1.30	7.85	5.53
Debt to equity	—	—	65.6%	66.4%
Interest cover (operating income ÷ interest)	n/m	n/m	0.8x	3.3x
Effective tax rate	—	—	—	−0.1%
R&D as % of revenue	38.2%	27.6%	12.5%	11.8%
Capital spending as % of revenue	7.3%	2.0%	2.0%	4.5%
Free cash flow ÷ net income	—	—	—	117.9%
Dividends and buybacks ÷ free cash flow	—	—	0.2%	17.3%

US$ thousands unless shown otherwise. Fiscal quarters.

Caris Life Sciences, Inc.: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Operating margin	−59.9%	−28.5%	−47.9%	−9.9%	15.1%	30.2%	2.4%	10.2%
Net margin	−66.6%	−28.4%	−84.8%	−39.6%	11.2%	28.0%	−0.2%	−0.2%
Free-cash-flow margin	−70.1%	−31.7%	−28.1%	3.3%	25.5%	13.6%	10.4%	2.4%
Current ratio	—	1.30	—	9.24	9.93	7.85	7.05	5.53
Debt to equity	—	—	—	82.5%	78.7%	65.6%	64.3%	66.4%
R&D as % of revenue	27.2%	20.9%	19.1%	13.8%	10.0%	10.9%	14.5%	12.3%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 5 checks passed · June 30, 2026

What it owns · $1.2bn

Short-term assets $1.1bnLonger-term assets $172m

What it owes, and who funded it · $1.2bn

Short-term liabilities $191mLonger-term liabilities $446mShareholders' equity $592m

Short-term assets cover short-term liabilities $1.1bn of assets due within a year against $191m of liabilities due within a year.
Short-term assets cover long-term liabilities $1.1bn short-term assets against $446m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Debt is 66% of equity.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt $169m of operating cash flow against $393m of debt.
Operating profit covers interest at least five times over Operating income of $153m against $47m of interest.

From Caris Life Sciences, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: CAI vs INNV CAI vs CRVL CAI vs PNTG

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from Caris Life Sciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Caris Life Sciences, Inc.